Nama's AI scorecard currently rates AptarGroup Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ATR's P/E ratio?

AptarGroup trades at a trailing price-to-earnings ratio of 26.5.

When does ATR report earnings?

AptarGroup's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $1.42.

What is the ATR price target?

The median analyst price target from 8 analysts is $158.00, with a range of $142.00 – $220.00.

Is ATR Shariah compliant?

Nama's AAOIFI-style screen reads AptarGroup as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does ATR pay a dividend?

Yes — AptarGroup's dividend yield is 1.4%.

Nama Insights

AptarGroup (ATR)

Healthcare · Medical Instruments Supplies · NYSE

AptarGroup (ATR) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $9.03B, a trailing price-to-earnings ratio of 26.5 and a free-cash-flow yield of 3.1%. Over the most recent reported fiscal year, revenue grew 5.4% and free cash flow per share fell 14.4%. Nama's AI scorecard rates it Hold, 5.5 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 5.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +3.7% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-20.0%

How far the last close sits under the highest price of the past five years.

Market cap	$9.03B
Trailing P/E	26.5
Price / book	3.5
Price / sales	2.3
FCF yield	3.1%
Dividend yield	1.4%
Gross margin	36.7%
Operating margin	13.0%
Net margin	10.0%
Revenue growth (YoY)	+5.4%
Revenue growth (3-yr annual)	+4.4%
EPS growth (YoY)	+1.6%
FCF/share growth (YoY)	-14.4%
Beta	0.3
Exchange	NYSE
Sector	Healthcare
Industry	Medical Instruments Supplies

ATR earnings

Next report: Feb 4, 2027 (Q4 2026, EPS estimate $1.42). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$1.52	$1.47	+3.4%	$1.02B
Q2 2026	Jul 30, 2026	$1.42	$1.35	+5.2%	—
Q1 2026	Apr 30, 2026	$1.19	$1.15	+3.5%	$982.87M
Q4 2025	Feb 5, 2026	$1.25	$1.23	+1.6%	$962.74M

ATR analyst price target

Median target $158.00 from 8 analysts, ranging $142.00 – $220.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live ATR data on Nama Insights →

Recent Congressional trades

AptarGroup trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025

ATR FAQ

Is ATR a buy?: Nama's AI scorecard currently rates AptarGroup Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ATR's P/E ratio?: AptarGroup trades at a trailing price-to-earnings ratio of 26.5.
When does ATR report earnings?: AptarGroup's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $1.42.
What is the ATR price target?: The median analyst price target from 8 analysts is $158.00, with a range of $142.00 – $220.00.
Is ATR Shariah compliant?: Nama's AAOIFI-style screen reads AptarGroup as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does ATR pay a dividend?: Yes — AptarGroup's dividend yield is 1.4%.